Aspire strengthens European footprint with Caragen buy

UK specialty generics company Aspire Pharma has acquired Caragen, an Ireland-based pharmaceutical organization with a strong presence in hospital immunology therapies.

Caragen brings extensive commercial expertise in hospital-based medicines and medical devices alongside being a well-established distribution network serving the pharmaceutical, medical device and healthcare sectors throughout Ireland.

Through this acquisition, Aspire will acquire the Irish distribution rights to more than 100 product lines covering a number of therapeutic areas including immunology, oncology, infectious diseases and medical devices.

The financial terms of the acquisition have not been disclosed.

Richard Condon, chief executive of Aspire, said: “This acquisition strengthens Aspire’s existing portfolio, broadens our reach into new therapeutic areas and significantly enhances our capabilities in Ireland.

“It represents another key milestone in our growth journey and marks the beginning of a new phase of strategic international expansion, as we steadily build our European footprint. By advancing our commercial and technical capabilities in Ireland, we are proud to accelerate our ability to serve patients and deliver meaningful value to healthcare systems across Europe and beyond.”

From a commercial operations standpoint, Caragen will continue to operate as an independent brand in Ireland. The company’s senior management team and team will also remain in place, ensuring a smooth integration and effective knowledge transfer into the broader Aspire ecosystem.

Andrew O’Connell, managing director of Caragen, said: “After building Caragen into a trusted partner for hospital-based therapies across Ireland, we are proud to be joining Aspire Pharma, which shares our commitment to quality, innovation and delivering the highest levels of patient care. 

“We look forward to expanding and accelerating new product launches in current and new channels in Ireland.”